CTIC 第二贴。

miku

？？？？？？？？？？

miku

kkkkkkkkkkkkkkk

miku

yyyyyyyyyyyyyyyyyy

miku

？？？？？？？？？？？？？？？？？？？？

miku

miku

什么东西？都看不到？

bennywt

卡贴？？？？？:@:@:@:@

bennywt

还在卡？？？:@:@:@:@

LaLaHem

CEO of Cell Therapeutics Inc. (ctic) James A Bianco sells 318,621 shares of ctic on 09/25/2009 at an average price of $1.19 a share.

Cell Therapeutic developing acquiring and commercializing novel treatments for cancer. Our goal is to build a leading vertically-integrated biopharmaceutical company with a diversified portfolio of oncology drugs and drug candidates. The company's research and in-licensing activities are concentrated on identifying new less toxic and more effective ways to treat cancer. The company has received fast-track designation from the FDA for this indication and expect to receive priority review which would expedite the FDA's review of our application. Cell Therapeutics Inc. has a market cap of $694.4 million; its shares were traded at around $1.24 with and P/S ratio of 60.8.

CEO又在卖shares了。。有点失去信心 。。

nggeewai

会不会 是他们在玩野 ?

白面包

连一堆ctic的director都在卖股，
看来ctic应该也是活不久了。。
星期一应该会低过1.10吧。。


(GuruFocus, September 26, 2009)Bio-tech joint Cell Therapeutic (CTIC) is in business of developing, acquiring and commercializing new treatments for cancer.

It has a market cap of $694.4 million; its shares were traded at around $1.24 with and P/S ratio of 60.8.

According to GuruFocus data, On September 25, there were a host of insider selling activities, involving five of the companies insiders: CEO James A Bianco (sold 318,621 shares), President Craig Philips (211,500 shares), EVP, Finance & Administration Louis A Bianco (105,580 shares), EVP, Corporate Communications Daniel G Eramian (104,276 shares), and EVP, Chief Medical Officer Jack W Singer (101,380 shares).

In the Form 4 forms filed with SEC for the transaction happened on September 25, 2009, it was market “ ( 1 ) Proceeds from the sale were primarily used to cover taxes related to the vesting of restricted stock on 9/25/2009.”

Separately, two weeks ago, CEO James A Bianco sold 1,366,108 more shares of CTIC stock on 09/11/2009 at the average price of $1.43, and back on August 14, 2009 Director Phillip M Phd Nudelman sold 164,000 shares of CTIC stock at the average price of $1.57.

No reason was given for the earlier sales.

On August 6, 2009, Cell Therapeutics announced for the quarter ended June 30, 2009, total net operating expenses decreased approximately 24% to $21.7 million, compared to $28.7 million for the same period in 2008. The decrease is mainly a result of a 54% reduction in research and development expenses for the quarter ended June 30, 2009, compared to the same period in 2008.

At the time, CTIC had approximately $12.0 million in cash and cash equivalents, securities available-for-sale, and interest receivable as of June 30, 2009. This does not include approximately $41.7 million, net of underwriting discount, the Company received in July 2009 in connection with an underwritten offering of common stock and warrants.

At the same time, the company announced it reduced outstanding debt by $52.9 million, representing 44.5% of outstanding debt, through exchange offers completed in June 2009, resulting in an estimated savings in future annual interest expense of approximately $3.3 million. In another words, debt to equity.

Then on August 21, 2009, the company announced it received $28.2 million from a sale of stock to a single investor. The investor bought Series 2 Preferred Stock shares, which were then converted to 18.9 million shares of common stock.

It financing activities that involved the debt holders and outsider investors do not lack confidence in the company, but the insider activities suggest the insiders have something else in their minds.

葉芬

CTIC Technical Analysis - The following is Cell Therapeutics ( CTIC ) stock technical analysis for September 28, 2009

Cell Therapeutics, Inc ( CTIC ) Support & Resistance Levels - 9/28/09

Resistance Levels: $1.40, $1.51, $1.57, $1.83

Support Levels: $1.10, $1.00, $0.97





Cell Therapeutics, Inc. (CTIC) broke down last week after it failed to hold both the 10 & 50 day moving averages on a closing basis. Besides the $1.10 low on Friday, there is no major support until $0.97-$1.00. Expect heavy selling pressure between $1.40-$1.50 if CTIC can get back to that area. I would be a buyer on a close above $1.50 or a retest of the 200 day moving average which is located at $0.83.

kelvinkai

葉芬,请问你还有HOLD CTIC 吗？。。你是多少钱买进的？。。还有，我朋友想买外国股，你是哪个地区的股票经纪？，可以PM你的电话给我吗？

葉芬

原帖由 kelvinkai 于 28-9-2009 02:00 PM 发表
葉芬,请问你还有HOLD CTIC 吗？。。你是多少钱买进的？。。还有，我朋友想买外国股，你是哪个地区的股票经纪？，可以PM你的电话给我吗？

我的CTIC還Hold著，只是暫時放她進雪柜冷藏。
我的本錢是在1.2多。。。

呵呵 我想你誤會了。
我並不是股票經紀。

在這裏我只是幫忙介紹我的那位服務1流的HouseDealer
給Cari網友開外國股票戶口。

你的朋友要開戶口。。
我現在就PM詳情給你，裏邊有聯絡電話。

miku

我卖了。。亏2500usd。。不过感觉很好。。再下去可能亏更多

m.i.k.e

Potential Breakthrough in Esophagus Cancer (CTIC)
Posted: October 1, 2009 at 6:31 am

Cell Therapeutics, Inc. (NASDAQ: CTIC) has announced what may be a large breakthrough in the fight against cancer.  This is a combined test rather than as a standalone treatment, but the result may be a huge step in cancer of the lower esophagus.  As many of the ties of one cancer are made to others, you can imagine that the hope might be that this would have other possibilities as well in the fight against other or related cancers.

The company said that a study from Brown University to be presented in the proffered oral session at the Annual Meeting of the International Society of Gastrointestinal Oncology in Philadelphia patients with cancer of the lower esophagus showed a high rate of complete remission when given OPAXIO(TM).  This is paclitaxel poliglumex, which is a biologically enhanced paclitaxel.  This result was shown when OPAXIO was administered in combination with standard cisplatin and concurrent radiation.

Cell Therapeutics noted that the phase II study was led by Dr. Safran and enrolled 40 patients with pathologically-confirmed and locally-advanced adenocarcinoma or squamous cell carcinoma of the esophagus or gastro-esophageal junction with no evidence of distant metastasis. These 40 patients received weekly paclitaxel poliglumex and cisplatin for six weeks with concurrent radiation. Of the first 28 patients undergoing surgery, all 8 of the 28 with adenocarcinoma have achieved a pathologic complete remission. No patients required a feeding tube, which differs from historical studies using the standard regimen where the large majority of patients require a feeding tube.

The company said that Paclitaxel poliglumex’s selective radiation enhancement preclinical profile is being validated by the high rates of pathologic complete remission, and by low rates of severe regional side effects observed in this phase 2 study. It also noted that the results justify proceeding to a randomized, controlled trial to definitively prove the clinical benefit observed.  It also plans to speak with the FDA regarding a potential phase III registration strategy for this indication.  Further noted is that this would ‘be the first registration study for a radiation sensitizing agent in this indication.’

As this is a $1.23 stock and has a 52-week trading range of $0.05 to $2.28, you can imagine there will be a lot of trading around this small cap name on Thursday.  Additional results and safety data is offered below.


JON C. OGG

Concurrent chemotherapy with 50.5 Gy of radiation is the standard pre-surgical therapy for patients with potentially resectable, locally-advanced esophageal cancer. Although the addition of chemotherapy to radiation is beneficial, the cure rate for esophageal cancer is low. Standard neoadjuvant treatment for esophageal cancer uses a regimen of cisplatin, and fluorouracil (5-FU) chemotherapy with concurrent radiation, which is a regimen associated with a high incidence of Grade 3-4 toxicity to the upper gastrointestinal track necessitating prophylactic insertion of feeding tubes. Published preclinical studies have demonstrated that, unlike standard paclitaxel and other chemotherapeutic agents that enhance radiation killing by a factor of 1.5 to 2.0, OPAXIO increases tumor specific radiation cell kill by a factor of 7.2 to 8.4-fold (Milas Luka et al, Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability, Int’l J. Radiat. Oncol. Biol. Phys. 55(3), 707-12 (2003)).
nutrition. No patients developed neuropathy.parenteral was given total subsequently in only one patient who was reported (n=2), fatigue (n=2), glucose intolerance (n=2), and hypersensitivity reaction (n=1). Grade 3 anorexia dysphagia. Eleven of 35 patients had grade 3 non-hematologic toxicities including electrolyte abnormalities (n=5), nausea (n=3), thromboembolus toxicities, which included electrolyte abnormalities, glucose intolerance, hypersensitivity reaction and non-hematologic (n=2) and anemia (n=1). Four of 35 patients experienced grade 4 neutropenia toxicities; grade 3 hematologic toxicity included hematologicThere were no grade 4

jochen

发生 出乎意料之外的事。。。。

看来要等明年 比较有看头。。。。
现在真的 可以收进 冰箱！，，，，

其实 我很渴望 他能下到 0.30 ，， 或更低。。。只要不倒。。

3个药。。。会回来的/。。。

JAV  之前 滑落。。。现在 也回到 ~ 2.00 的价位。。。。

只要不倒。。。。


当然 消息 股 要小心。。。
最近 有人 买到  sequenom 吗？？ 《--这种 才可怕。。

葉芬

原帖由 jochen 于 1-10-2009 08:42 PM 发表
发生 出乎意料之外的事。。。。

看来要等明年 比较有看头。。。。
现在真的 可以收进 冰箱！，，，，

其实 我很渴望 他能下到 0.30 ，， 或更低。。。只要不倒。。

3个药。。。会回来的/。。。

JAV  之 ...

好心你啦，Jochen小弟。。要是CTIC真的下到0.30，會很多人罵罵聲
在我們這一Group里有很多人買CTIC，我不希望3月份的股價會再次發生。

pink0905

不要吓我 ～我的买价是１。５８。 不懂要不要在买来average价格？

SUNNY仔

原帖由 pink0905 于 2-10-2009 04:46 PM 发表
不要吓我 ～我的买价是１。５８。 不懂要不要在买来average价格？

你怕什么...我的是5000 X $1.8...